Navigation Links
Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director

ROCKVILLE, Md., March 1, 2013 /PRNewswire-USNewswire/ -- Accelovance announces the addition of Ralph Boccia , MD, FACP as the Oncology Medical Director.  The addition of Dr. Boccia is a strong compliment to the oncology strength the Maryland-based CRO that caters to biotech and small/mid pharma Sponsors.  In addition to his responsibilities at Accelovance, Dr. Boccia is a founder and the Medical Director of the Center for Cancer and Blood Disorders.  He also is an active Clinical Associate Professor of Medicine at Georgetown University and consulting Medical Director of the International Oncology Network (ION) Clinical Research Program.

Accelovance offers innovative clinical solutions focused on oncology that accelerate study start up timelines; existing partnerships with leading oncology academic institutions and improved  access to target patient populations that in turn control study budgets.  Such solutions are ideal for Phase I/II and ClinPharm studies where speed, quality and cost-effectiveness are critical to support Sponsor business goals. This model mirrors the highly successful approach utilized by Accelovance with their vaccine and infectious disease programs.

"We are thrilled to have a recognized leader in medical oncology and hematology, Dr. Ralph V. Boccia , join our organization.  His 31 years of practice and clinical research are an asset to the clients we serve as we help define patient populations, study protocols and program approaches," remarked Stephen J. Trevisan , Accelovance President and Chief Executive Officer. "His addition complements our oncology experienced CRO team that has had tremendous growth over the last 12 months in clinical operations, project management and data management."

"It is a unique opportunity to join a forward-thinking, patient-centric clinical services company like Accelovance. This team's commitment to advancing the novel oncology therapies has real value to Sponsors.  We are actively talking to companies with promising technology and it is quite exciting," commented Ralph V. Boccia , MD, FACP.  He is a board-certified Medical Oncologist with specialties in internal medicine and hematology.  Dr. Boccia earned his medical degree at the University of Minnesota and completed training in internal medicine at UCLA-affiliated hospitals.  His hematology, oncology and bone marrow transplant fellowships were completed at the combined UCLA-VA program at the National Cancer Institute (NCI) at the National Institutes of Health in Bethesda, Maryland.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. The Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance has a 100% owned subsidiary providing CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at

Media Contact:
Garrett D. Smith
Phone: 240.238.4914

SOURCE Accelovance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amedica Expands Patent Portfolio with Proprietary Silicon Nitride Total Disc Implant to Treat Neck and Back Pain
2. Cephasonics Expands Market Presence, Enters Ultrasound Research Market with Large-Channel-Count Modular System Offering Up to 4,096 Channels
3. Hyland Software Expands its Partnership with Nuance Communications to Improve Efficient Care Models at Healthcare Facilities
4. DSI Renal Expands Georgia Presence with Conyers and Kennesaw Dialysis Clinics
5. Cogmedix Expands To Support Laser Based Medical Devices
6. Heraeus Expands Its Venus White Line of Whitening Maintenance and Oral Care Products
7. CryoLife Expands Stock Repurchase Program
8. Modulus Expands Offerings with Patch Design and Manufacturing
9. BioElectronics Expands to the Czech & Slovak Republic
10. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
11. Marken Expands Regulatory And Technical Excellence In Logistics
Post Your Comments:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):